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Abstract 
Keratinocytes expressing tumour or viral antigens can be eliminated by 
antigen primed CD8 cytotoxic T cells.   CD4 T helper cells help induction of 
CD8 cytotoxic T cells from naïve precursors  and generation of CD8 T cell 
memory.  Here we show, unexpectedly,that CD4 cells are also required to 
assist primed CD8 effector T cells in rejection of skin expressing hGH, a neo-
self antigen, in keratinocytes. The requirement for CD4 cell help can be 
substituted by CD40 co-stimulation. Rejection of skin expressing OVA, a non-
self antigen, by primed CD8 cytotoxic T cells can in contrast occur without 
help from antigen specific CD4 T cells.  However, rejection of OVA expressing 
keratinocytes is helped by antigen specific CD4 T cells if only low numbers of 
primed or naïve OVA specific CD8 T cells are available. Effective 
immunotherapy directed at antigens expressed in squamous cancer may 
therefore be facilitated by induction of tumour antigen specific CD4 helper T 
cells as well as cytotoxic CD8 T cells. 
 
 
 
 
   
Introduction 
Development of epithelial malignancy is regulated by the immune system, as 
chronic immunosuppression after organ transplantation is associated with a 
greatly increased risk of squamous cancer.  Many cancers of epithelial origin  
express tumour specific  modified self proteins as neo-self antigens 
(Buckwalter and Srivastava, 2008).  Epithelial cancer can also arise from skin 
persistently infected with virus, including human papillomavirus (Al-Daraji and 
Smith, 2009) and Merkel tumour associated retrovirus (Feng et al., 2008), and  
these tumours continue to express virus encoded antigen.   Evidently, neo-
self or viral antigens expressed in squamous epithelial cancer fail to induce an 
immune response adequate to eliminate the cancer. Better understanding of 
the requirement for effective immune mediated elimination of keratinocytes 
expressing viral or neo self antigen would therefore assist in the design of 
appropriate immunotherapeutic interventions for squamous epithelial cancer.  
We have developed a  murine model to study the requirements for effective 
immunotherapy directed at antigen expressed in keratinocytes. Skin 
expressing a non-self or neo-antigen as a transgene in keratinocytes from a 
keratin promoter is grafted to a syngeneic non transgenic recipient(Zhong et 
al., 2004).  This allows us to study the requirements for inducing and 
delivering an effective immune response to antigen expressed only in 
keratinocytes, and not directly presented to the immune system by 
professional antigen presenting cells(APC).  
The fate of a graft of skin expressing non self antigen in keratinocytes 
depends on the antigen.   Some antigens including papillomavirus non-
   
structural proteins fail to invoke spontaneous  rejection of grafts (Dunn et al., 
1997),  allowing study of the requirements for effective induction of immunity 
after antigen cross presentation from keratinocytes.  Other antigens, including 
ovalbumin(Holcmann et al., 2009) and human growth hormone(Zhong et al., 
2004), which is closely related in sequence to mouse growth hormone and 
therefore a neo-self antigen in the mouse, induce spontaneous graft rejection, 
allowing study of elimination of keratinocytes by primed T cells in a second 
graft following immune mediated elimination of a priming graft.   
To prime a cytotoxic CD8 effector T cell response from naïve antigen specific 
CD8 T cell precursors, antigens expressed only in epithelial cells must be 
cross-presented by professional APC, particularly dermal dendritic cells in the 
local lymph node (Bedoui et al., 2009).  CD4 helper T cells are required to 
enable priming of  memory and effector CD8 T cells (Schuurhuis et al., 
2000;Janssen et al., 2003;Smith et al., 2004).  CD4 T cells also assist in the 
maintenance of a pool of memory CD8 T cells(Sun et al., 2004). However,  
once they are primed by antigen, CD8 effector T cells are held capable of 
elimination of their cognate target cells without the need for CD4 T cell help. 
Recent  in vitro evidence suggests however that CD4 T cells can assist in 
secondary responses to cross-presented but not directly presented 
antigen(Blachere et al., 2006).  We have also previously shown a requirement 
for CD4 cells in a secondary immune response to human growth hormone in 
FVB mice of H-2q x H-2b genetic background (Zhong et al., 2008).  To extend 
this observation to mice of a genetic background more commonly used for 
studies of immune physiology and therefore enable further dissection of the 
mechanisms by which CD4 cells contribute to elimination of keratinocytes 
   
following priming or immunisation, we created K14.hGH transgenic mice on a 
C57/Bl6 genetic background.  We evaluated the role of CD4 T cells in 
rejection of epithelial cells expressing various non-self antigens using these 
mice. Here we present data showing that CD4 T cell help improves the 
efficacy of rejection by already primed CD8 effector T cells of skin expressing 
either non self antigen or neo-self antigen in keratinocytes, and demonstrate 
that the requirement for CD4 cell responses can be substituted by CD40 co-
stimulation. 
   
Results 
Second-set syngeneic skin grafts expressing hGH as a neo-self antigen are 
more rapidly rejected by C57Bl/6 recipients than the primary graft 
We grafted skin expressing antigen as a transgene in keratinocytes to naïve 
C57Bl/6 (C57) recipient animals, and measured time to graft rejection to 
assess the immune response induced to the expressed antigen. We first 
studied recall responses to human growth hormone (hGH), a near homologue 
of mouse growth hormone representing modified self (neo-self).  Animals  that 
rejected a hGH transgenic graft were considered  primed to hGH, and 
received a further hGH graft. Primary hGH grafts on C57 mice were rejected 
in a median of 31.5 days (Fig. 1A), as was observed for C57 x FVB mice and 
in  contrast to the findings for FVB mice, which rarely reject primary hGH 
grafts (Zhong et al., 2004).  Second hGH grafts placed on graft primed C57 
recipients were rejected with a median survival time of 21 days, significantly 
earlier than the initial graft (p=0.018). The recall response to hGH by C57 
mice is consistent with observations for FVB x C57 mice (Zhong et al., 2004). 
Rejection of second-set hGH skin grafts requires CD4 cells 
Rejection by FVB  x C57 mice of skin expressing hGH antigen in 
keratinocytes requires both CD4 and CD8 T cells (Zhong et al., 2004;Zhong et 
al., 2008).   To establish, for C57 mice, whether CD4 T cells are required for 
rejection of hGH transgenic skin following priming, hGH graft primed C57 
animals were depleted of CD4 T cells, and given a second  hGH graft (Fig 
1B).  Rejection of second hGH grafts occurred in 8% (1/13) of CD4 depleted 
recipients, compared with 87% (7/8) of CD4 replete recipients (p<0.0001). 
   
Thus, CD4 T cells are important not only for priming but also for optimal 
rejection by CD8 T cells of hGH grafts from an hGH graft primed C57animal. 
 CD40 stimulation abrogates the requirement for CD4 cells in rejection of 
second-set K14hGH.H-2b skin grafts 
CD4 T helper cells provide co-stimulatory signals to dendritic cells to assist in 
priming  antigen-specific primary cytotoxic T cell responses (Schoenberger et 
al., 1998). Co-stimulatory signals delivered by dendritic cells to activated T 
cells have recently been shown to play a significant role in secondary immune 
responses  (Wang et al., 2007;Salek-Ardakani et al., 2008) . We therefore  
investigated whether CD40 stimulation could replace the requirement for CD4 
T cells and enable effector T cell function and hence graft rejection in an hGH 
primed animal. Mice that had rejected an hGH graft were depleted of CD4 T 
cells, re-grafted with a further  hGH graft, and treated with agonist anti-CD40 
antibody to provide a costimulatory signal, or with control rat serum,  at 0, 5, 
10, 15 and 20 days post-grafting. Rejection of second hGH grafts occurred in 
53% (8/15) of mice receiving the CD40 stimulatory antibody FGK45 (Fig. 2B), 
and in 0% (0/6) mice receiving rat IgG, demonstrating that CD40 stimulation 
could substitute for primed antigen specific CD4 cells in promoting graft 
rejection by CD8 T cells from a primed animal, and suggesting that re-
exposure of primed CD8 T cells to antigen presented by professional APC is 
required for optimal function. 
 Primed, OVA-specific CD8 T cells can reject second-set OVA-expressing 
skin grafts without the need for help 
   
To examine further how help from CD4 T cells enables CD8 T cell mediated 
rejection of skin grafts in antigen primed recipients, we used an antigen, 
ovalbumin, for which CD8 and CD4 MHC Class I and II restricted epitopes are 
known, and for which mice with T cells transgenic for T cell receptors 
recognising CD4 and CD8 restricted OVA epitopes are available. We first 
grafted skin from mice expressing a membrane associated form of OVA from 
a keratin 5 promoter (K5-mOVA).  K5-mOVA graft recipients successfully 
rejected their grafts, with a median survival time of 19 days. OVA graft primed 
recipients were then depleted of CD4 cells, and received a second K5-mOVA 
graft on the opposite flank. CD4 T cell depleted and OVA graft primed 
recipients of a second K5-mOVA graft rejected the second graft with a median 
survival time of 12 days, significantly shorter than the time to primary graft 
rejection  (p=0.01; Fig. 3A) and no different to the rejection time (12 days) for 
OVA graft primed and otherwise unmanipulated animals  
To confirm that there was no requirement for CD4 cells for rejection of OVA 
grafts by OVA specific T cells,  we examined the response to a graft 
expressing a minimal CTL epitope of OVA (SIINFEKL) expressed from a 
keratin 14 promoter  (K14.SIIN), and hence unable to invoke antigen specific 
CD4 cells. K14SIIN skin grafts were rejected by 12 of 15 unprimed recipients, 
in a median of 21 days. Recipients that had rejected a first K14.SIIN graft 
were depleted of CD4 cells, and regrafted. Ten of 10 recipients rejected a 
repeat graft, in a median of 11 days (p<0.0001; Fig. 3B) similar to that for 
OVA grafts.    To further investigate whether MHC Class 1 restricted CD8 T 
cells are sufficient for rejection of K5.mOVA grafts, 1x106 Rag1-/- OT-I cells, 
specific for the MHC-1 restricted SIINFEKL peptide, were transferred to  
   
immune deficient Rag1-/- recipients(n=4), that were then grafted with K5-
mOVA grafts. Four of 4 grafts were rejected, with a median survival time of 10 
days (Fig. 5A).  Thus, CD8 T cells are sufficient to reject skin  grafts 
expressing either OVA or the major MHC Class 1 restricted CD8 epitope of 
OVA. in keratinocytes. 
CD4 T cells alone are not sufficient for graft rejection 
To establish whether CD4 T cells alone could effect rejection of a K5.mOVA 
graft, 2.5x107  OT-II spleen cells, specific for a CD4 restricted epitope of OVA, 
were transferred into Rag1-/- recipients(n=16), which 3 days later received a  
K5.mOVA skin graft. FACS staining of peripheral blood on the day of grafting 
confirmed successful transfer of CD4 T cells(Fig 4).  K5.mOVA grafts (13/16) 
were generally accepted by immunodeficient Rag 1 -/- animals whether or not 
they received  OVA specific CD4 OT-II T cells (p=0.37; Fig. 4), in contrast to 
the findings for OVA specific CD8 T cells described above. Thus OVA specific 
CD4 T cells are unable, in the absence of OVA specific CD8 cytotoxic T cells,  
to reject OVA expressing skin grafts.  
The number of transferred Rag-OT-I spleen cells determines the rate of 
K5mOVA graft rejection  
As CD4 T cells are necessary for rejection of skin expressing hGH but not 
OVA from naïve and antigen primed animals, and are insufficient to achieve 
rejection of skin grafts without CD8 T cells, we investigated whether CD4 T 
cells might accelerate CD8 T cell-mediated K5.mOVA skin graft rejection.   
OT-I OVA specific CD8 cytotoxic T cells (106) were transferred with or without  
OT- II OVA specific CD4 helper T cells  (106) to immunodeficient recipient 
   
animals, 3 days prior to grafting with K5m.OVA skin. Grafts were rejected in a 
median of 10 days whether or not OT-II cells were transferred (Fig 5B). To 
establish whether CD4 cells might contribute to rejection when antigen 
specific CD8 T cells were present in limiting numbers,  graded number of 
Rag-OT-1 OVA specific CD8 spleen cells, combined with sufficient irrelevant 
TCR transgenic T cells to equalise the total number of transferred T cells and 
minimise T cell activation through homeostatic proliferation which would 
otherwise occur in the T cell deficient Rag 1 -/- recipient.   Rejection of OVA 
grafts from these immune reconstituted animals was fastest in animals 
recipient of larger numbers of transferred OT-1 cells (p=0.0082; Fig. 5A).  To 
determine whether there was a role of OVA specific helper CD4 T cells in 
graft rejection when OVA specific CD8 cell numbers were limiting, 102 OVA 
specific CD8 T cells  were transferred to 2C TCR transgenic recipients, which 
have normal numbers of T cells without any OVA specific T cell repertoire. 
OVA specific OT-1 CD8 T cells of “naïve” phenotype as shown (Figure 6 A,B) 
were transferred with or without 106 OVA specific OT-II  CD4 T cells(Fig. 5C). 
K5.mOVA skin grafts were rejected from recipients of OVA specific CD8 
spleen cells alone with a median survival time of 40 days. When  both OVA 
specific CD8 and OVA specific CD4 T  cells were transferred,  median graft 
survival time was significantly shorter at 16 days (p=0.022). Thus in animals 
with physiological precursor frequencies of antigen specific CD8 T cells of 
100-1000 (Lammermann and Sixt, 2008) antigen specific CD4 T cells 
enhance skin graft rejection.  
CD4 T cell help for memory CD8 T cells.  
   
OVA specific CD4 T cells might enhance OVA graft rejection by OVA specific 
CD8 cells in the previously described experiments by assisting with the 
priming of naïve OVA specific CD8 T cells.  To  investigate whether  memory 
CD8 T cell function could also be enhanced by CD4 T cells, we created CD8 
memory T cells specific for OVA  in vitro by a protocol shown to produce cells 
predominantly of  a central memory phenotype (CD44CD62Lhi) , and 98% of 
the cells demonstrated this phenotype (Fig 6).  Memory phenotype OVA 
specific CD8  OT-1 cells (100/animal)  were then transferred to Rag1-/- C57  
mice bearing a K5.mOVA skin graft , with or without 106 CD4 enriched OVA 
specific cells from OT-II mice (Fig 6C).    Grafts were rejected by mice 
receiving OT-1 CD8 central memory T  cells alone with a median graft survival 
time of 24 days. Mice receiving both OT-I CD8 central memory T cells  and 
OT-II OVA specific CD4 cells (n=7) rejected grafts more quickly, with a 
median survival time of 12 days (p=0.008; Fig 6D). Thus, OVA specific CD4 T 
cells enhanced graft rejection by activated OVA specific CD8 T cells, 
confirming that  antigen specific CD4 T cells can assist primed antigen 
effector and memory CD8 T cell function in eliminating skin grafts expressing 
antigen in keratinocytes.  
   
Discussion 
The data presented here show that antigen specific CD4 T cells can enhance 
the function of antigen primed effector and memory CD8 T cells, and hence 
enable, or increase the rapidity of, rejection of keratinocytes expressing non  
or neo self antigen.  Further, the function of CD4 T cells can be substituted by 
CD40 stimulation, suggesting that the likely mechanism of CD4 mediated 
enhancement is activation of APCs cross presenting antigen to CD8 T cells.  
These findings provide in vivo evidence to complement previous in vitro 
generated data (Blachere et al., 2006) that CD8 effector function is enhanced 
by antigen specific CD4 T cells, and extend this finding specifically to 
keratinocyte elimination.   Our previous observations for hGH antigen on an 
F1 (H-2 b x H-2q) genetic background demonstrated that CD8 T cells were 
necessary for elimination of keratinocytes, that CD4 T cells assisted the 
process, and that antibody, although induced, was not sufficient to enable 
rejection (Zhong et al., 2004;Zhong et al., 2008). Extension of this observation 
from H-2q  to H-2b mice eliminates the possibility that the previous findings 
represented a genetically determined limitation of CD8 T cell function in F1 
(H-2q x H-2b) animals, as H-2q mice did not present hGH  as a neo-self 
antigen for rejection.  
As the mechanism by which epithelial cells expressing antigen are eliminated 
by CD8 T cells is uncertain, it was important to establish that CD4 T cells 
themselves were not effecting  graft rejection where antigen was expressed in 
keratinocytes, as it is well recognised that allograft rejection can occur via an  
CD4 dependent and MHC class II restricted mechanism(Rosenberg et al., 
1989).Large numbers of antigen specific CD4 T cells were unable to induce 
   
graft rejection in our model, indicating that direct cellular cytotoxicity by CD4 T 
cells is unlikely to account for help provided in enhancement of skin graft 
rejection in this system. 
CD4 T cells assist priming of naïve CD8 T cells (Mintern et al., 2002c), 
activating DCs to express co-stimulatory molecules, and providing key 
cytokines for CD8 T cell expansion including IL-2. High precursor frequencies 
of antigen-specific CD8 T cells can overcome the need for CD4 T cells, as 
evidenced by ovalbumin-specific cytotoxicity ex vivo of OT-I T cells generated 
in MHC II-deficient hosts(Mintern et al., 2002b;Mintern et al., 2002a;Wang et 
al., 2007;Salek-Ardakani et al., 2008). The precursor frequency of antigen-
specific CD8 T cells determines the fate of skin grafts, and previous 
experiments have established that for priming of responses to OVA, 
expressed constitutively in all cells including APC, higher precursor frequency 
abrogates the need for CD28- and CD154-mediated co-stimulation to expand 
the precursor pool(Ford et al., 2007). However, while priming can occur in the 
absence of help from antigen specific CD4 T cells, particularly if CD8 cells 
generate their own IL-2, availability of antigen specific CD4 cells at priming 
appears critical for generation of central memory CD8 T cells(Fernando et al., 
2002;Fuse et al., 2009;Castellino and Germain, 2007a).     
More recently, CD4 T cells have also been shown in vitro to play a role in the 
reactivation of  memory cells through an mechanism in which Il-2 plays a part, 
though it cannot entirely substitute for CD 4 cells(Blachere et al., 2006).  In 
our experiments, OT-I OVA specific CD8 T cells were sufficient to reject a 
K5mOVA graft from a Rag -/- mouse, and the rate of rejection was related to 
the number of transferred Rag OT-I cells.  Thus, at least for OVA, the 
   
requirement for CD4 T cells is not absolute, and likely assists in amplification 
of effector numbers.  IL-2 dependent proliferation of CD8 memory cells 
(Mintern et al., 2002c) is important in increasing cell numbers, and production 
of IL-2 by OT-1 cells in response to antigen is well described.  Proliferation of 
CD8 cells can occur locally in the target tissue (Wakim et al., 2008b;Kim et al., 
2009) and CD4 T cells may help activate local dendritic cells (Wakim et al., 
2008a) as these have also been shown to play a role in enabling memory T 
cell function, or upregulate MHC Class 1 presentation on KC, as these cells 
can also promote proliferation of antigen specific T cells in vivo,  even in the 
absence of professional APC (Kim et al., 2009). Our data however show that 
as OT-1 cells are sufficient to enable rejection of well healed skin grafts from 
CD4 deficient animals, local dendritic cell activation and CD4 T cell induction 
are not mandatory for CD8 effector function for a non self antigen, as they 
appear to be for a neo-self antigen,  but rather assist in amplifying the CD8 
effector response. We have previously established in a graft model where the 
target antigen is the E7 protein of HPV 16 that the inflammation associated 
with grafting promotes local CD8 effector T cell function in an antigen primed 
host, as well healed grafts are relatively resistant to CD8 T cell 
function(Matsumoto et al., 2004).  In the hGH graft rejection model, where the 
antigen is a neo self antigen, and partial tolerance would be expected(Zhong 
et al., 2004), inflammation and CD4 cells were required for CD8 effector 
function, and we now show that CD40 co-stimulation was able to substitute for 
CD4 T cells, as has been shown in other systems (Hernandez et al., 2008). 
Our system differs from previous data in demonstrating the enhancement of a 
secondary immune response by CD40 co-stimulation. This suggests a role for 
   
CD40 signalling in antigen presentation to memory CD8 T cells. Together, 
these data demonstrate that the likely in vivo mechanism of enhancement of 
skin graft rejection by CD4 cells and local inflammation involves effective 
cross presentation of antigen by CD4 activated APC in skin to enable 
amplification of CD8 T effector cells.  Alternatively, albeit less likely, direct 
CD40 stimulation of CD8 T cells may enhance CTL function and could 
account for rejection mediated by CD40 stimulation in this system(Bourgeois 
et al., 2002). A further mechanism by which inflammation may promote graft 
rejection is through chemokine mediated attraction of T cells(Castellino and 
Germain, 2007b), both antigen specific and non specific(Wakim et al., 2008b), 
to the site of grafting, enabling selective proliferation of antigen specific 
effector cells.   
Elucidation of the cellular requirements for an effective immune response to 
antigen cross-presented at epithelium has significant clinical relevance. 
Failure to clear chronic HPV infection leads in some cases to cervical cancer, 
and many epithelial cancers express tumour specific antigens. Both non self 
antigen and neo-self antigen presentation in these clinical scenarios is 
chronic, invoking regulatory rather than effector CD4 responses, Our data 
demonstrate that absence of antigen specific helper  CD4 T cells may 
significantly impair the effectiveness of  effector or memory CD8 T cell 
responses to neo-self antigen in keratinocytes, whether the immune response 
is induced by specific immunotherapy or in response to antigen cross 
presented from an epithelial tumour.  They therefore support the need for 
induction of appropriate CD4 T cell responses as part of any 
immunotherapeutic intervention targeted at epithelium.   
   
Materials and Methods 
Mice 
All experimental protocols were approved by the animal ethics committee of 
the University of Queensland. Mice were maintained under conventional 
conditions in specific pathogen-free holding rooms in the Princess Alexandra 
Hospital Biological Resources Facility, University of Queensland.  
Transgenic mice used in these studies are detailed in Table 1. OT-II and 
K5m.OVA mice were obtained from Dr W.R. Heath, Walter and Eliza Hall 
Institute, Parkville, Australia.  OT-I and Rag1-/- mice were purchased from the 
Animal Resource Centre, Perth Australia. 2C mice were obtained from Dr B. 
Fazekas, Centenary Institute, Sydney. K14hGH.H-2b mice were produced by 
back-crossing male K14hGH. H-2q  mice obtained from Dr Jie Zhong, 
Diamantina Institute with C57Bl/6 mice for 10 generations. To assess whether 
backcrossing had successfully generated a C57Bl/6 background, offspring not 
expressing hGH were used as skin graft donors. Ear skin grafts applied to the 
flanks of C57Bl/6 recipients were uniformly accepted, indicating 
histocompatibility.  
Screening of transgenic mice 
To screen for the K14.hGH transgene, serum hGH was assayed using the 
Bioclone Elegance Growth Hormone ELISA Kit according to the 
manufacturer’s instructions. To screen for the K5.mOVA transgene, DNA from 
tail tips was detected by PCR with forward primer 5’-CTG TGC AGA TGA 
TGT AC-3’ and reverse primer 5’-TGG TTG CGA TGT GCT TG-3’. 
   
Skin grafting 
Whole-thickness ear skin grafting was performed as previously 
described(Frazer et al., 1998). Grafts were examined every second day and 
were classified as rejected if there was >80% loss of epithelium, and as 
accepted if there was no rejection by day 50. Rejection or acceptance of 
transgenic skin was confirmed genetically and histologically in a random 
sample of mice.  Where repeat grafting was undertaken it was performed on 
the opposite flank. 
CD4 cell depletion 
CD4 cells were depleted by intraperitoneal injection with anti-CD4 mAb 
(GK1.5) at 1mg/mouse, 3 days prior to grafting. An equal amount of rat IgG 
was used as a control. Efficacy of depletion was evaluated by FACS staining 
of 100-200μL peripheral blood. Briefly, peripheral blood mononuclear cells 
were prepared and washed with FACS buffer (1% FCS in PBS). Cells were 
stained with FITC-conjugated anti-CD4 (RM4-4, BD Biosciences, San Jose, 
CA; RM4-4 does not cross-compete with GK1.5) and phycoerythrin-
conjugated anti-CD3 (BD Biosciences) mAbs and visualized with flow 
cytometry. 
Monoclonal antibody production 
Anti mouse-CD40 agonist Rat IgG2a antibody was isolated from FGK45 
hybridoma cells used with permission of Professor Antionius Rolink (Basel 
Institute, Switzerland). Briefly, FGK45 cells were cultured, and protein 
produced was isolated with a protein G column and quantified by the 
   
NanoDrop 1000 spectrophotometer. Rat IgG was prepared by separating an 
immunoglobulin enriched fraction of rat serum by ammonium sulphate 
precipitation. The product was dialysed against PBS, filtered (0.2µm filter) and 
the protein concentration measured by BCA Protein Assay kit (Pierce).  
Antibody was administered according to a published schedule (Fischbein et 
al., 2000) shown effective in our laboratory . 
Preparation and transfer of spleen cells 
A single cell suspension of spleen cells in DMEM (Invitrogen) was prepared. 
Red cells were lysed by addition of 2mL ACK lysing buffer (Invitrogen, 
Carlsbad, CA), and cells  washed in sterile PBS.  Cell viability was determined 
by trypan blue (Invitrogen) dye exclusion.    
In vitro activation of OT-1 T cells 
OT-I T cells were in vitro activated as described by Kenna et al(Kenna et al., 
2008). Briefly, OT-I lymph node cells were harvested and cultured in complete 
RPMI (RPMI 1640 supplemented with 1mM sodium pyruvate, 0.1mM 
nonessential amino acids, 50μM 2-ME) with 1% normal mouse serum, 
0.1μg/mL OVA257-264 and 10ng/mL interleukin-2. After 3 days, cells were 
harvested and washed (3x) with RPMI 1640 and re-cultured in 6-well plates at 
2x106/mL in the absence of antigen but with 10ng/mL IL-15 for an additional 5 
days. Cells were harvested, wash and resuspended in sterile PBS prior to 
transfer into recipients.  
Purification of OT-II cells by positive selection 
   
A single cell suspension of OT-II spleen cells was resuspended at 90μL 4% 
foetal bovine serum in sterile PBS per 107 cells and incubated with MACS 
anti-CD4 beads [Miltenyi Biotech, Bergisch Gladbach, Germany] (10μL beads 
per 107 total cells) for 15 min at 4oC. Magnetic separation was performed with 
the autoMACS Separator using the Possel positive selection programme as 
per manufacturer’s instructions [Miltenyi Biotec]. Purity was assessed by 
FACS staining with anti-CD4 (FITC conjugated, BD Pharmingen), and anti-
CD3 (PE conjugated, eBioscience). Cells were washed twice in sterile PBS 
prior to transfer. 
Statistics 
The statistical comparisons were determined by Mantel-Cox analysis of 
Kaplan-Meier survival curves. Differences with p <0.05 were considered 
significant.  
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Figure Legends 
 
FIGURE 1   hGH graft primed animals require CD4 T cells for optimal second 
graft rejection. A,B: Graft survival time is shown for (A) naïve or K14hGH.C57 
graft primed C57Bl/6 animals (n=12) that received a K14hGH.C57 or a 
C57Bl/6 graft, and (B) K14hGH.C57 graft primed animals that received a 
K14hGH.C57 graft with or without simultaneous depletion of CD4 T cells.  
Graft survival was compared using log-rank (Mantel- Cox) test. Multiple mice 
rejecting grafts on the same day are shown as a single graph point on that 
day. C,D. For control antibody treated (C) and GK1.5 anti CD4  treated (D) 
animals, efficacy of CD4 cell depletion was assessed by flow cytometry 
analysis of peripheral blood, using  anti-CD4 and anti-CD3 mAb. Percentage 
of CD4 cells at 7 days are shown for each treatment.  Results are combined 
from two experiments.  
FIGURE 2 CD40 stimulation abrogates the requirement for CD4 cells to 
enable rejection of hGH grafts from hGH primed animals. (A) Graft  survival 
over time  for K14hGH.C57 grafts (n=15) and for C57Bl/6 grafts (n=6) placed 
on hGH graft primed and CD4 depleted C57Bl/6 recipients treated with 
agonist CD40 antibody FKG 45.  (B) Graft  survival over time  for 
K14hGH.C57 grafts placed on graft primed and CD4 depleted C57Bl/6 
recipients treated either with agonist CD40 antibody (n=15) or with control 
antibody  (n=6). Graft survival differences were assessed for significance 
using log-rank (Mantel- Cox) test. Results are from three separate 
experiments. 
   
FIGURE 3   Ovalbumin and SIINFEKL-expressing skin grafts do not require 
CD4 cells for rejection. (A) Graft survival over time is shown for K5.mOVA 
grafts placed on naïve, or OVA graft primed and CD4 depleted, C57Bl/6 
recipient animals (n=12) ,   (B) Graft survival over time is shown for  K14 
SIINFEKL  grafts placed on naïve or SIINFEKL graft primed and CD4 
depleted C57Bl/6 recipient animals (n=12). Survival differences were 
assessed for significance using log-rank (Mantel- Cox) test. 
 
FIGURE 4   Transfer of CD4 T cells alone does not significantly increase graft 
rejection. (A) Survival over time of OVA grafts placed on immunodeficient  
Rag1-/- recipients (n=16) reconstituted with  106 OVA specific helper T cells 
from OT-II transgenic spleen or on control Rag 1 -/- animals  receiving no 
cells (n=8).   (B,C) Effective transfer  of OVA specific helper T cells from OTII 
mice  was confirmed by staining of peripheral blood from mice receiving OT-II 
cells (B) and control mice(C) with anti-CD3 and anti-Vα2 antibodies specific 
for OT-II cells. Results are from two separate experiments. 
 
FIGURE 5   The rate of K5mOVA graft rejection is dependent on CD8 
precursor frequency and CD4 T cells  A,  Immunodeficient Rag1-/- recipients 
of K5.mOVA grafts received increasing numbers of Rag-/- OTI OVA specific 
CD8 T cells from spleen as shown together with sufficient irrelevant  TCR 
transgenic T cells to equalise the number of transferred cells,  and graft 
survival was observed (n=>4 per group).  B, Rag-OT-I OVA specific CD8 T 
cells from spleen (106) were administered  with (n=4)  or without ( n=4)   OVA 
   
specific T helper (OT-II) spleen cells (106)  to immunodeficient Rag1-/- 
recipients.  After 3 days, K5mOVA skin grafts were placed and followed to 
rejection.  C, Rag -/- 2C immunodeficient  mice received 102  OVA specific CD8 
OT-1 cells , or 102 OT-1 cells and 106 OVA specific CD4 OT-2 cells.  
K5.mOVA skin grafts were placed and followed to rejection.  Graft survival 
over time is shown. Survival differences were assessed for significance using 
log-rank (Mantel- Cox) test. Results are from two separate experiments.  
FIGURE 6   CD4 T cells provide help to activated CD8 T cells. (A, B)  OT-I 
CD8 Ova specific T cells, either activated in vitro (Left panels) or not so 
activated (“ Naïve”; right panels)  were assessed for CD8, CD44(A) or 
CD62L(B) expression by flow cytometry.  (C) OT-II spleen cells were enriched 
for OVA specific T helper cells using anti-CD4 magnetic beads and 
enrichment  assessed with anti-CD4 and CD3 antibodies by flow cytometry.  
D. Mice received 102 activated OVA specific  CD8 OT-I cells (n=7) or 102 
activated OT-I and 106 CD4-enriched OVA specific helper OT-II cells (n=7).   
K5.mOVa skin grafts were placed and followed to rejection. Graft survival over 
time  is shown. Survival differences were assessed for significance using log-
rank (Mantel- Cox) test.
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Figure 6 
 
 
   
Table 1 
Designation of transgenic animals 
Designation  Genetic 
background 
Transgene genotype Phenotype Function Reference 
OT-II H-2b T cell receptor gene specific 
for OVA323-339 peptide bound 
on IAb 
Most T cells are CD4 helper T cells specific 
for OVA presented in the context of MHC 
Class II 
Source of CD4 helper T cells 
specific  for OVA presented by 
antigen presenting cells 
(Barnden et 
al., 1998 
OT-1 
 
H-2b Rag -/- T cell receptor gene specific 
for OVA peptide SIINFEKL 
bound on H-2 Kb   No 
recombinase activation genes 
All T cells are CD8 cytotoxic T cells specific 
for OVA presented in the context of MHC 
Class I 
Source of CD8 cytotoxic T cells 
specific for OVA presented by 
somatic cells 
(Hogquist et 
al., 1994) 
K5.mOVA H-2b OVA expressed from a keratin 
5 promoter  
Squamous epithelial keratinocytes express 
OVA peptides for direct and cross 
presentation 
Source of skin presenting OVA 
in somatic cells  that can also be 
cross presented by antigen 
presenting cells  
(Azukizawa 
et al., 2003) 
K14.SIIN H-2b OVA  MHC Class I restricted 
peptide SIINFEKL expressed 
from a keratin 14 promoter 
 
Squamous epithelial keratinocytes express 
OVA peptide for direct presentation to CD8 
T cells. Also express low levels of human 
growth hormone due to leaky transgene 
contstruct 
Source of skin presenting ing 
OVA peptide in somatic cells  
that cannot be cross presented 
by antigen presenting cells 
(McGargill et 
al., 2002) 
2C H-2b T cell receptor gene specific 
for H-2 Ld   
No recombinase activation 
genes 
All T cells are CD8 cytotoxic  T cells specific 
for an irrelevant foreign MHC molecule 
A mouse with normal numbers 
of T cells none of which can 
recognise OVA  
H-2Ld  (Sha 
et al., 1990): 
K14hGH  H-2q 
Or 
H-2b 
Human growth hormone 
expressed from a keratin 14 
promoter 
 
Squamous epithelial keratinocytes express 
human growth hormone peptides for direct 
and cross presentation 
Source of skin presenting 
human growth hormone  in 
somatic cells  that can also be 
cross presented by antigen 
presenting cells 
(Zhong et al., 
2004) 
 
